S100A14

Summary

S100A14 (S100 calcium binding protein A14, HGNC:18901) is a protein-coding gene on chromosome 1q21.3, encoding Protein S100-A14 (Q9HCY8). Modulates P53/TP53 protein levels, and thereby plays a role in the regulation of cell survival and apoptosis.

This gene encodes a member of the S100 protein family which contains an EF-hand motif and binds calcium. The gene is located in a cluster of S100 genes on chromosome 1. Levels of the encoded protein have been found to be lower in cancerous tissue and associated with metastasis suggesting a tumor suppressor function (PMID: 19956863, 19351828).

Source: NCBI Gene 57402 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 25 total
• MANE Select transcript: NM_020672

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18901
Approved symbol	S100A14
Name	S100 calcium binding protein A14
Location	1q21.3
Locus type	gene with protein product
Status	Approved
Aliases	S100A15, BCMP84
Ensembl gene	ENSG00000189334
Ensembl biotype	protein_coding
OMIM	607986
Entrez	57402

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 6 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000344616, ENST00000368700, ENST00000368701, ENST00000368702, ENST00000469571, ENST00000476873, ENST00000859573, ENST00000946612

RefSeq mRNA: 1 — MANE Select: NM_020672 NM_020672

CCDS: CCDS1046

Canonical transcript exons

ENST00000344616 — 4 exons

Exon	Start	End
ENSE00001387931	153616295	153616325
ENSE00003619904	153615235	153615381
ENSE00003630533	153615829	153615936
ENSE00003890238	153614255	153615022

Expression profiles

Bgee: expression breadth ubiquitous, 206 present calls, max score 99.94.

FANTOM5 (CAGE): breadth broad, TPM avg 26.8678 / max 1473.6466, expressed in 437 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
14689	26.8505	436
14688	0.0173	6

Top tissues by expression

281 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	99.94	gold quality
pharyngeal mucosa	UBERON:0000355	99.63	gold quality
esophagus mucosa	UBERON:0002469	99.60	gold quality
mucosa of transverse colon	UBERON:0004991	99.46	gold quality
tongue squamous epithelium	UBERON:0006919	99.36	gold quality
skin of abdomen	UBERON:0001416	99.28	gold quality
oral cavity	UBERON:0000167	99.08	gold quality
body of tongue	UBERON:0011876	99.01	gold quality
skin of leg	UBERON:0001511	98.84	gold quality
gingiva	UBERON:0001828	98.83	gold quality
rectum	UBERON:0001052	98.82	gold quality
gingival epithelium	UBERON:0001949	98.79	gold quality
zone of skin	UBERON:0000014	98.61	gold quality
esophagus squamous epithelium	UBERON:0006920	98.41	gold quality
mammalian vulva	UBERON:0000997	98.21	gold quality
penis	UBERON:0000989	98.05	gold quality
squamous epithelium	UBERON:0006914	97.93	gold quality
epithelium of esophagus	UBERON:0001976	97.81	gold quality
nasal cavity epithelium	UBERON:0005384	97.75	gold quality
nipple	UBERON:0002030	97.71	gold quality
tongue	UBERON:0001723	97.66	gold quality
ileal mucosa	UBERON:0000331	97.51	gold quality
cervix epithelium	UBERON:0004801	97.51	gold quality
mouth mucosa	UBERON:0003729	97.41	gold quality
hair follicle	UBERON:0002073	97.38	gold quality
duodenum	UBERON:0002114	97.35	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	97.24	gold quality
upper arm skin	UBERON:0004263	97.19	gold quality
minor salivary gland	UBERON:0001830	97.15	gold quality
upper leg skin	UBERON:0004262	96.73	gold quality

Single-cell (SCXA)

Detected in 17 experiment(s), a significant marker in 16.

Experiment	Marker?	Max mean expression
E-HCAD-1	yes	8744.09
E-MTAB-8142	yes	5265.10
E-MTAB-8060	yes	2023.79
E-CURD-79	yes	1992.03
E-CURD-114	yes	1880.29
E-MTAB-8221	yes	1545.78
E-MTAB-10885	yes	1405.08
E-MTAB-8495	yes	1191.86
E-MTAB-10662	yes	588.81
E-ANND-5	yes	573.54
E-MTAB-8410	yes	62.70
E-MTAB-5061	yes	26.93
E-HCAD-10	yes	25.33
E-MTAB-10553	yes	24.89
E-HCAD-9	yes	10.80

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

19 targeting S100A14, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-5004-5P	99.68	66.63	1294
HSA-MIR-6871-3P	99.43	68.85	741
HSA-MIR-3678-3P	99.31	67.10	1432
HSA-MIR-6852-5P	99.17	66.69	2073
HSA-MIR-4477A	98.83	69.75	2952
HSA-MIR-4451	98.82	68.17	1455
HSA-MIR-7977	98.65	66.18	2590
HSA-MIR-450A-2-3P	97.91	67.56	1459
HSA-MIR-4456	97.50	64.88	1678
HSA-MIR-6841-5P	97.19	67.29	409
HSA-MIR-6736-3P	96.98	65.22	1342
HSA-MIR-624-5P	96.00	68.88	728

Literature-anchored findings (GeneRIF, showing 31)

• Data constitute strong evidence in support of the notion that S100A14 might function as a cancer suppressor working in the P53 pathway and play a role in esophageal carcinogenesis. (PMID:19351828)
• S100A14 and S100A4 have roles in metastasis in colorectal cancer after surgery (PMID:19956863)
• S100A14 induces cell apoptosis is partially in a RAGE-dependent manner (PMID:21559403)
• S100A14 provides a novel role in oral squamous cell carcinoma cell proliferation by inducing G1-arrest (PMID:22032898)
• that S100A14 promotes cell motility and invasiveness by regulating the expression and function of MMP2 in a p53-dependent manner. (PMID:22451655)
• The solution structure of homodimeric S100A14 in the apo state solved by NMR (PMID:23197251)
• High S100A14 expression is associated with metastasis of hepatocellular carcinoma. (PMID:23886191)
• S100A14 interacts with S100A16 and regulates its expression in human cancer cells. (PMID:24086685)
• Data demonstrate that S100A14 is transcriptionally regulated by JunB and involved in esophageal squamous cell carcinoma cell differentiation. (PMID:24107296)
• Data show that S100A14 and HER2 are colocalized in plasma membrane of breast cancer tissue cells and breast cancer cell lines. (PMID:24285542)
• Data indicate that S100A14 has a crucial role in EOC progression, and its overexpression is associated with poor prognosis. (PMID:24939856)
• Data show that the genetic variant 425G>A on the 5’-UTR of calcium-binding protein S100A14 was associated with reduced S100A14 expression in gastric cancer (GC) cells. (PMID:25266115)
• The antimicrobial peptides psoriasin (S100A7) and koebnerisin (S100A15) suppress extracellular matrix production and proliferation of human fibroblasts (PMID:25502330)
• Co-expression of S100A14 and S100A16 correlates with a poor prognosis in human breast cancer and promotes cancer cell invasion (PMID:25884418)
• S100A14 is expressed in epithelial-like, but not in mesenchymal-like, triple-negative breast cancer cells in vitro. (PMID:25912829)
• We identified a two-gene signature including KCNN4 and S100A14 which was related to recurrence in optimally debulked serous ovarian carcinoma patients (PMID:27270322)
• Increased S100A15 expression and decreased DNA methylation of its gene promoter region were associated with high metastasis potential and poor outcome in lung adenocarcinoma. (PMID:28498804)
• results indicate that S100A14 may have a role in the induction of differentiation and inhibition of cell metastasis in gastric cancer. (PMID:28726786)
• S100A14 is expressed in a subset of lung adenocarcinoma, and its expression is related to certain clinicopathological parameters. Furthermore, S100A14 expression was strongly correlated with migration and invasion in lung adenocarcinoma cells. (PMID:28950283)
• S100A14 increases the motility of lung adenocarcinoma cells, and might be a diagnostic and prognostic serum biomarker and potential therapeutic target for lung adenocarcinoma. (PMID:29733545)
• Low S100A14 expression is associated with Colorectal Cancer. (PMID:31882495)
• Loss of S100A14 expression at the tumor-invading front correlates with poor differentiation and worse prognosis in oral squamous cell carcinoma. (PMID:32202693)
• A S100A14-CCL2/CXCL5 signaling axis drives breast cancer metastasis. (PMID:32483412)
• S100A14 suppresses metastasis of nasopharyngeal carcinoma by inhibition of NF-kB signaling through degradation of IRAK1. (PMID:32555330)
• S100A14 serum level and its correlation with prognostic factors in breast cancer. (PMID:32984913)
• S100A14 promotes progression and gemcitabine resistance in pancreatic cancer. (PMID:33579599)
• S100A14 inhibits cell growth and epithelial-mesenchymal transition (EMT) in prostate cancer through FAT1-mediated Hippo signaling pathway. (PMID:33890248)
• Circ_0003221 Downregulation Restrains Cervical Cancer Cell Growth, Metastasis and Angiogenesis by Governing the miR-139-3p/S100A14 Pathway. (PMID:35023052)
• Construction of immune-related signature and identification of S100A14 determining immune-suppressive microenvironment in pancreatic cancer. (PMID:35953822)
• Induction of Antimicrobial Protein S100A15 Expression by Oral Microbial Pathogens Is Toll-like Receptors-Dependent Activation of c-Jun-N-Terminal Kinase (JNK), p38, and NF-kappaB Pathways. (PMID:36982421)
• LncRNA CTBP1-AS inhibits TP63-mediated activation of S100A14 during prostate cancer progression. (PMID:38476086)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	s100s	ENSDARG00000036773
danio_rerio	s100a10a	ENSDARG00000037425
danio_rerio	s100t	ENSDARG00000055589
mus_musculus	S100a14	ENSMUSG00000042306
rattus_norvegicus	S100a14	ENSRNOG00000069413

Paralogs (21): CRNN (ENSG00000143536), S100A8 (ENSG00000143546), S100A7 (ENSG00000143556), S100B (ENSG00000160307), S100A1 (ENSG00000160678), S100A11 (ENSG00000163191), S100A9 (ENSG00000163220), S100A12 (ENSG00000163221), S100P (ENSG00000163993), S100G (ENSG00000169906), S100Z (ENSG00000171643), S100A7A (ENSG00000184330), S100A3 (ENSG00000188015), S100A16 (ENSG00000188643), SNTN (ENSG00000188817), S100A13 (ENSG00000189171), S100A4 (ENSG00000196154), S100A5 (ENSG00000196420), S100A2 (ENSG00000196754), S100A10 (ENSG00000197747), S100A6 (ENSG00000197956)

Protein

Protein identifiers

Protein S100-A14 — Q9HCY8 (reviewed: Q9HCY8)

Alternative names: S100 calcium-binding protein A14

All UniProt accessions (1): Q9HCY8

UniProt curated annotations — full annotation on UniProt →

Function. Modulates P53/TP53 protein levels, and thereby plays a role in the regulation of cell survival and apoptosis. Depending on the context, it can promote cell proliferation or apoptosis. Plays a role in the regulation of cell migration by modulating the levels of MMP2, a matrix protease that is under transcriptional control of P53/TP53. Does not bind calcium.

Subunit / interactions. Homodimer. Interacts with AGER.

Subcellular location. Cytoplasm.

Tissue specificity. Expressed at highest levels in colon and at moderate levels in thymus, kidney, liver, small intestine, and lung. Low expression in heart and no expression is seen in brain, skeletal muscle, spleen, placenta and peripheral blood leukocytes.

Similarity. Belongs to the S-100 family.

RefSeq proteins (1): NP_065723* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011992	EF-hand-dom_pair	Homologous_superfamily
IPR013787	S100_Ca-bd_sub	Domain

Pfam: PF01023

UniProt features (11 total): helix 5, strand 2, turn 2, chain 1, domain 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2M0R	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HCY8-F1	77.33	0.30

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 179 (showing top): GOBP_MYELOID_LEUKOCYTE_MIGRATION, GOBP_CELL_CHEMOTAXIS, JAEGER_METASTASIS_DN, AREB6_01, GGGTGGRR_PAX4_03, GOBP_REGULATION_OF_LEUKOCYTE_MIGRATION, GOBP_LEUKOCYTE_CHEMOTAXIS, GOBP_REGULATION_OF_MONONUCLEAR_CELL_MIGRATION, KANG_FLUOROURACIL_RESISTANCE_DN, GOBP_POSITIVE_REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS, GOBP_TAXIS, GOBP_LEUKOCYTE_MIGRATION, GOBP_REGULATION_OF_IMMUNE_RESPONSE, RICKMAN_METASTASIS_DN, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM

GO Biological Process (7): apoptotic process (GO:0006915), response to lipopolysaccharide (GO:0032496), toll-like receptor 4 signaling pathway (GO:0034142), defense response to bacterium (GO:0042742), calcium ion homeostasis (GO:0055074), positive regulation of granulocyte chemotaxis (GO:0071624), positive regulation of monocyte chemotaxis (GO:0090026)

GO Molecular Function (4): calcium ion binding (GO:0005509), chemokine receptor binding (GO:0042379), calcium-dependent protein binding (GO:0048306), protein binding (GO:0005515)

GO Cellular Component (4): obsolete extracellular space (GO:0005615), perinuclear region of cytoplasm (GO:0048471), extracellular exosome (GO:0070062), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
positive regulation of leukocyte chemotaxis	2
cellular anatomical structure	2
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
response to molecule of bacterial origin	1
response to lipid	1
response to oxygen-containing compound	1
cell surface toll-like receptor signaling pathway	1
defense response	1
response to bacterium	1
monoatomic cation homeostasis	1
inorganic ion homeostasis	1
granulocyte chemotaxis	1
regulation of granulocyte chemotaxis	1
monocyte chemotaxis	1
positive regulation of mononuclear cell migration	1
regulation of monocyte chemotaxis	1
metal ion binding	1
G protein-coupled receptor binding	1
cytokine receptor binding	1
calcium ion binding	1
protein binding	1
binding	1
cytoplasm	1
extracellular vesicle	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

706 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
S100A14	S100A16	Q96FQ6	802
S100A14	HRNR	Q86YZ3	777
S100A14	RNF6	Q9Y252	683
S100A14	DLEC1	Q9Y238	669
S100A14	NUCB1	Q02818	665
S100A14	LZTS1	Q9Y250	650
S100A14	S100A7A	Q86SG5	643
S100A14	S100A2	P29034	604
S100A14	S100A6	P06703	594
S100A14	S100A3	P33764	591
S100A14	S100A5	P33763	582
S100A14	S100A1	P23297	570
S100A14	ADH1B	P00325	544
S100A14	S100A7	P31151	542
S100A14	S100Z	Q8WXG8	541

IntAct

64 interactions, top by confidence:

A	B	Type	Score
XRCC5	XRCC6	psi-mi:“MI:0914”(association)	0.970
S100A14	S100A16	psi-mi:“MI:0915”(physical association)	0.780
S100A16	S100A14	psi-mi:“MI:0915”(physical association)	0.780
ASF1A	HAT1	psi-mi:“MI:0914”(association)	0.640
CEP20	CEP20	psi-mi:“MI:0915”(physical association)	0.590
S100A14	MAGEA6	psi-mi:“MI:0915”(physical association)	0.560
S100A13	S100A14	psi-mi:“MI:0915”(physical association)	0.560
ERBB2	NDUFA4	psi-mi:“MI:0914”(association)	0.530
S100A14	MYH9	psi-mi:“MI:0407”(direct interaction)	0.440
S100A14	SLC8A1	psi-mi:“MI:0407”(direct interaction)	0.440
TRPM4	S100A14	psi-mi:“MI:0407”(direct interaction)	0.440
S100A14	GOT1	psi-mi:“MI:0915”(physical association)	0.400
AKT1	S100A14	psi-mi:“MI:0915”(physical association)	0.370
AURKA	S100A14	psi-mi:“MI:0915”(physical association)	0.370
S100A14	CASP8	psi-mi:“MI:0915”(physical association)	0.370
FGFR2	S100A14	psi-mi:“MI:0915”(physical association)	0.370
SMAD4	S100A14	psi-mi:“MI:0915”(physical association)	0.370
STK11	S100A14	psi-mi:“MI:0915”(physical association)	0.370
ECH1	A2ML1	psi-mi:“MI:0914”(association)	0.350
ZIC1	IMPA2	psi-mi:“MI:0914”(association)	0.350
NEDD4	HMGB1P1	psi-mi:“MI:0914”(association)	0.350
PRDM16	GAPDHS	psi-mi:“MI:0914”(association)	0.350
TDRKH	GGCT	psi-mi:“MI:0914”(association)	0.350
HTRA4	PSMD12	psi-mi:“MI:0914”(association)	0.350
ATG16L1		psi-mi:“MI:0914”(association)	0.350

BioGRID (75): S100A14 (Two-hybrid), S100A16 (Two-hybrid), S100A14 (Affinity Capture-RNA), S100A14 (Affinity Capture-MS), S100A14 (Affinity Capture-MS), S100A14 (Affinity Capture-MS), S100A14 (Affinity Capture-MS), S100A16 (Two-hybrid), S100A14 (Affinity Capture-MS), S100A14 (Two-hybrid), S100A14 (Two-hybrid), S100A14 (Two-hybrid), S100A14 (Two-hybrid), S100A14 (Two-hybrid), S100A14 (Two-hybrid)

ESM2 similar proteins: A5PJN0, A8J3A0, F1SSF9, O73763, O76038, O81223, O81445, O93409, P02613, P04113, P05938, P05944, P05963, P08051, P08052, P13543, P18087, P30644, P45961, Q01449, Q02045, Q06A97, Q0P571, Q0VFG3, Q10131, Q3HRN7, Q3HRN9, Q3HRP0, Q3HRP2, Q3HRP5, Q3MHP3, Q5QIT3, Q5XJX1, Q63ZJ3, Q6R556, Q75KU4, Q7XC27, Q8CD10, Q8IYU8, Q8LAS7

Diamond homologs: O77691, O77791, P02632, P02633, P02634, P02638, P02639, P04163, P04271, P04631, P05109, P05942, P05943, P05964, P06702, P06703, P07091, P08207, P10462, P14069, P20930, P23297, P24479, P24480, P25815, P26447, P27003, P27005, P28318, P28782, P28783, P29034, P29377, P30801, P31725, P31949, P31950, P33763, P33764, P35466

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

25 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	21
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

682 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:153614957:G:C	F81L	0.994
1:153614957:G:T	F81L	0.994
1:153614959:A:G	F81L	0.994
1:153615266:A:G	L49P	0.994
1:153615325:A:C	F29L	0.992
1:153615325:A:T	F29L	0.992
1:153615327:A:G	F29L	0.992
1:153614947:A:G	W85R	0.991
1:153614947:A:T	W85R	0.991
1:153615326:A:G	F29S	0.989
1:153615351:C:G	A21P	0.989
1:153615275:A:G	L46P	0.988
1:153615338:A:G	L25P	0.987
1:153614925:G:T	A92D	0.986
1:153615355:C:A	E19D	0.986
1:153615355:C:G	E19D	0.986
1:153615251:A:G	L54P	0.985
1:153614948:G:C	F84L	0.984
1:153614948:G:T	F84L	0.984
1:153614950:A:G	F84L	0.984
1:153614958:A:C	F81C	0.984
1:153614958:A:G	F81S	0.984
1:153615290:A:G	L41P	0.984
1:153615347:A:T	I22N	0.983
1:153615338:A:T	L25H	0.980
1:153615356:T:A	E19V	0.980
1:153614945:C:A	W85C	0.979
1:153614945:C:G	W85C	0.979
1:153615290:A:T	L41Q	0.976
1:153614949:A:G	F84S	0.975

dbSNP variants (sampled 300 via entrez): RS1001624922 (1:153615290 A>G), RS1001836786 (1:153615047 C>A,T), RS1003413657 (1:153617881 C>T), RS1003633157 (1:153617791 C>T), RS1003665967 (1:153618139 C>T), RS1004208200 (1:153617513 C>T), RS1004474835 (1:153613928 A>C,G,T), RS1004931918 (1:153616928 G>C), RS1005418348 (1:153615186 G>A), RS1005498546 (1:153616585 CAG>C), RS1005738345 (1:153618111 G>A), RS1006973156 (1:153614196 C>T), RS1008006357 (1:153615934 G>A,C), RS1009065027 (1:153617160 G>C,T), RS1010355132 (1:153616519 G>A)

Disease associations

OMIM: gene MIM:607986 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

57 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, affects cotreatment	5
sodium arsenite	decreases expression, increases expression	3
perfluorooctanoic acid	increases expression, decreases expression	2
mercuric bromide	increases expression, affects cotreatment	2
Benzo(a)pyrene	decreases methylation, increases expression	2
Phenylmercuric Acetate	increases expression, affects cotreatment	2
Tobacco Smoke Pollution	affects expression, increases expression	2
Cyclosporine	increases expression	2
Aflatoxin B1	increases expression, increases methylation, decreases expression	2
Cadmium Chloride	increases abundance, decreases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, increases expression	2
aristolochic acid I	increases expression	1
dicrotophos	decreases expression	1
methyleugenol	increases expression	1
bisphenol A	decreases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
beta-lapachone	increases expression	1
methylparaben	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
butyraldehyde	increases expression	1
cupric chloride	decreases expression	1
lewisite	increases expression	1
isobutyl alcohol	affects cotreatment, increases abundance, increases expression	1
perfluoro-n-nonanoic acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
ICG 001	decreases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
bisphenol S	decreases expression	1
Oxaliplatin	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.